Biogen Gets FDA Approval for Milestone Hemophilia Therapy

The U.S. FDA has approved Biogen Idec's Alprolix, the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news